C
Corina E. Dutcus
Researcher at Eisai
Publications - 106
Citations - 10878
Corina E. Dutcus is an academic researcher from Eisai. The author has contributed to research in topics: Lenvatinib & Pembrolizumab. The author has an hindex of 30, co-authored 103 publications receiving 6763 citations. Previous affiliations of Corina E. Dutcus include Dartmouth–Hitchcock Medical Center.
Papers
More filters
Journal ArticleDOI
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo,Richard S. Finn,Shukui Qin,Kwang Hyub Han,Kenji Ikeda,Fabio Piscaglia,Ari David Baron,Joong-Won Park,Guohong Han,Jacek Jassem,Jean-Frédéric Blanc,Arndt Vogel,Dmitry Komov,T.R. Jeffry Evans,Carlos Lopez,Corina E. Dutcus,Matthew Guo,Kenichi Saito,Silvija Kraljevic,Toshiyuki Tamai,Min Ren,Ann-Lii Cheng +21 more
TL;DR: Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma and the safety and tolerability profiles of lenvatinIB were consistent with those previously observed.
Journal ArticleDOI
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger,Makoto Tahara,Lori J. Wirth,Bruce G. Robinson,Marcia S. Brose,Rossella Elisei,Mouhammed Amir Habra,Kate Newbold,Manisha H. Shah,Ana O. Hoff,Andrew G. Gianoukakis,Naomi Kiyota,Matthew H. Taylor,Sung Bae Kim,Monika K. Krzyzanowska,Corina E. Dutcus,B.D.L. Heras,J. Zhu,Steven I. Sherman +18 more
TL;DR: Lenvatinib, as compared with placebo, was associated with significant improvements in progression-free survival and the response rate among patients with iodine-131-refractory thyroid cancer.
Journal ArticleDOI
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
Javier Cortes,Joyce O'Shaughnessy,David Loesch,Joanne L. Blum,Linda T. Vahdat,Katarina Petrakova,Philippe Chollet,Alexey Manikas,Véronique Diéras,Thierry Delozier,Vladimir Vladimirov,Fatima Cardoso,Han Koh,Philippe Bougnoux,Corina E. Dutcus,Seth Seegobin,Denis Mir,Nicole Meneses,Jantien Wanders,Chris Twelves +19 more
TL;DR: Eribulin showed a significant and clinically meaningful improvement in overall survival compared with TPC in women with heavily pretreated metastatic breast cancer, challenging the notion that improved overall survival is an unrealistic expectation during evaluation of new anticancer therapies in the refractory setting.
Journal ArticleDOI
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer,Boris Alekseev,Sun Young Rha,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,Evgeny Kopyltsov,María José Méndez-Vidal,Vadim Kozlov,Anna Alyasova,Sung Hoo Hong,Anil Kapoor,Teresa Alonso Gordoa,Jaime R. Merchan,Eric Winquist,Pablo Maroto,Jeffrey C. Goh,Miso Kim,Howard Gurney,Vijay Patel,Avivit Peer,Giuseppe Procopio,Toshio Takagi,Bohuslav Melichar,Frederic Rolland,Ugo De Giorgi,Shirley Wong,Jens Bedke,Manuela Schmidinger,Corina E. Dutcus,Alan D. Smith,Lea Dutta,Kalgi Mody,Rodolfo F. Perini,Dongyuan Xing,Toni K. Choueiri +37 more
TL;DR: In this article, Lenvatinib in combination with pembrolizumab or everolimus has been shown to have activity against advanced renal cell carcinoma (RCC).
Journal ArticleDOI
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer,Thomas E. Hutson,Hilary Glen,M. Dror Michaelson,Ana M. Molina,Timothy Eisen,Jacek Jassem,Jakub Zolnierek,J. P. Maroto,Begoña Mellado,Bohuslav Melichar,Jiri Tomasek,Alton Kremer,Han-Joo Kim,Karen Wood,Corina E. Dutcus,James Larkin +16 more
TL;DR: Lenvatinib plus everolimus and len vatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy.